1. Triple inhaled therapy in COPD patients: determinants of prescription in primary care.
- Author
-
Vetrano DL, Zucchelli A, Bianchini E, Cricelli C, Piraino A, Zibellini M, Ricci A, Onder G, and Lapi F
- Subjects
- Adrenal Cortex Hormones administration & dosage, Adrenal Cortex Hormones adverse effects, Adrenal Cortex Hormones therapeutic use, Adrenergic beta-2 Receptor Agonists administration & dosage, Adrenergic beta-2 Receptor Agonists adverse effects, Adrenergic beta-2 Receptor Agonists therapeutic use, Aged, Aged, 80 and over, Comorbidity, Disease Progression, Drug Therapy, Combination adverse effects, Drug Therapy, Combination methods, Female, Follow-Up Studies, Humans, Italy epidemiology, Male, Middle Aged, Muscarinic Antagonists administration & dosage, Muscarinic Antagonists adverse effects, Muscarinic Antagonists therapeutic use, Outcome Assessment, Health Care, Practice Guidelines as Topic, Pulmonary Disease, Chronic Obstructive epidemiology, Respiratory Therapy trends, Primary Health Care statistics & numerical data, Pulmonary Disease, Chronic Obstructive drug therapy, Respiratory Therapy methods
- Abstract
Objective: To assess the incidence and determinants of the triple inhaled therapy in chronic obstructive pulmonary disease (COPD) primary care patients., Methods: Data derived from the Health Search Database (HSD) gathering information on 700 Italian general practitioners. A cohort of COPD patients, prescribed for the first time with inhaled treatments, was followed-up between January 2002 and December 2014. The outcome was the first incident prescription of a triple inhaled therapy, namely the combination of inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA). Cox regressions were used to test the association (hazard ratios, HR) between candidate determinants and the outcome., Results: Out of 17589 patients (mean age 71.1 ± 11.3 years; 37.4% females), 3693 (21%) were prescribed with a triple inhaled therapy during follow-up. Older age (HR = 1.79 to 2.61), current and former smoking habit (HR = 1.72 and 1.66), higher GOLD stage (HR = 1.45 to 2.79), the number of moderate and severe COPD exacerbations (HR = 1.10 to 2.63), and heart failure (HR = 1.17) resulted statistically significantly associated with an increased incident prescription of the triple inhaled therapy. Female sex (HR = 0.80) and some comorbidities (HR = 0.21 to 0.87) resulted negatively associated with the outcome. Furthermore, patients initially treated with LAMA (HR = 1.5) and LABA/ICS (HR = 1.23) were more likely to escalate to the triple therapy, than those on LABA. Conversely, patients initially treated with ICS presented a negative hazard (HR = 0.72)., Conclusions: The knowledge of demographic and clinical determinants of the escalation to the triple inhaled therapy in real-world COPD patients may help clinicians to better personalize respiratory pharmacological treatments of their patients, and inform international societies that issue clinical guidelines., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF